PLAT and Sepsis: Moreover, the Second Multicentre Intrapleural Sepsis Trial (MIST2) has demonstrated that combined tissue plasminogen activator (t-PA) and DNase treatment exhibits notable therapeutic efficacy and is highly cost-effective [208].